Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOTOMA: Perioperative Durvalumab + Tremelimumab in Resectable HCC
NCT05440864Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Oct 2023
- Primary completion
- Nov 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab and durvalumab in hepatocellular carcinoma (HCC), sponsored by University Health Network. Primary endpoint: Number of greater than grade 3 adverse events (AEs) or immune related adverse events that leads to treatment cessation at 4 years. Started Oct 2023; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05440864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05440864.